2–4% of high-grade ovarian cancer patients display abnormalities of Anaplastic Lymphoma Kinase (ALK) expression due to either gene copy number gain or to the formation of the ALK fusion gene ALK:FN1; this finding indicates the existence of a potential therapeutic target in a minority of ovarian cancer patients [23]. This evidence concerns the gene ALK and ovarian cancer.